Mike Stedman
Research Subjects
Research Interests
Mike Stedman has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Hugh Heald
University of Manchester Manchester UK
39 shared publications - Anthony A. Fryer
School of Medicine, Keele University, Keele, UK
12 shared publications - Christopher J. Duff
School of Medicine, Keele University, Keele, UK
7 shared publications - Martin Brunel Whyte
University of Surrey, Guildford, UK
7 shared publications - Pensee Wu
School of Medicine, Keele University, Keele, UK
7 shared publications David Holland
The Benchmarking Partnership, Smart Innovation Hub, Keele University, Keele, UK
5 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (4) , 372-385
Evaluating the Link Between Thyroid Function Test Results and Levothyroxine Dose in the Management of Hypothyroidism: Can We Improve Dosing Regimes?
Introduction: Over 10 million thyroid function tests (TFTs) are carried out in England each year, most requests coming from primary care. Our previous work showed that only 25% of results for patients being treated with Levothyroxine fell within the TSH/FT4 boundary circumscribing 75% of untreated individuals. This study aimed to investigate further the differences in thyroid hormone levels, taking into account both diagnostic code and amounts prescribed. Methods: Using a city‐wide population record, we analysed TSH/FT4 simultaneous results from 47,869 consecutive diagnosed hypothyroid individuals by medication dose and 393,101 untreated/euthyroid individuals over 14 years. For those on medication, we only included those who were diagnosed over 2 years ago, had no more than two tests per year and more than 2 years of test results available. For those not on medication, we included results from those patients who had a single test or two tests with more than 4 years between tests. Results: The FT4 distribution for Levothyroxine‐treated individuals was similar in shape versus untreated individuals but shifted towards higher FT4 even at the lowest dose of Levothyroxine, with an increasing separation of the distributions as Levothyroxine dose increased ( F value = 1.5 increasing to F value = 4.2). In contrast, the distribution of TSH was substantially different for untreated individuals versus those on Levothyroxine, where the distribution was massively skewed to low or undetectable TSH with a ‘hockey stick’ configuration, with increasing skewness as doses of Levothyroxine rose. For those not on thyroid hormone replacement, 90.3% of individuals were within the TSH reference range and of these, 0.8% were recorded with a low FT4. For those on medication, only 43.8% were within the TSH reference range. For men versus women, the median Levothyroxine dose was higher in all decades, with the highest median daily dose at age 50–59 years (men: 107 mcg/day; women 93 mcg/day). Median T4 rose (women > men) and TSH fell progressively (women > men) by age in treated individuals. The levels of TSH in treated and untreated populations were only similar at around FT4 = 20pmol/L: below this treated patients have a higher TSH and above it, treated have a lower TSH for the same FT4. Conclusion: We have here described that distribution of FT4/TSH is different in people on and off Levothyroxine treatment. For those on Levothyroxine, only 43.8% were within the TSH reference range and the degree of difference increased in treated individuals with Levothyroxine daily dose. The potential implication of our findings is that clinicians must be mindful as they diagnose and treat hypothyroidism that the administration of Levothyroxine, while in most but not all individuals is clinically beneficial does not return the individual to the same balance of TSH and FT4 as seen in euthyroid individuals.
- 22 December 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (4) , 372-385
Open AccessEvaluating the Link Between Thyroid Function Test Results and Levothyroxine Dose in the Management of Hypothyroidism: Can We Improve Dosing Regimes?
Introduction: Over 10 million thyroid function tests (TFTs) are carried out in England each year, most requests coming from primary care. Our previous work showed that only 25% of results for patients being treated with Levothyroxine fell within the TSH/FT4 boundary circumscribing 75% of untreated individuals. This study aimed to investigate further the differences in thyroid hormone levels, taking into account both diagnostic code and amounts prescribed. Methods: Using a city‐wide population record, we analysed TSH/FT4 simultaneous results from 47,869 consecutive diagnosed hypothyroid individuals by medication dose and 393,101 untreated/euthyroid individuals over 14 years. For those on medication, we only included those who were diagnosed over 2 years ago, had no more than two tests per year and more than 2 years of test results available. For those not on medication, we included results from those patients who had a single test or two tests with more than 4 years between tests. Results: The FT4 distribution for Levothyroxine‐treated individuals was similar in shape versus untreated individuals but shifted towards higher FT4 even at the lowest dose of Levothyroxine, with an increasing separation of the distributions as Levothyroxine dose increased ( F value = 1.5 increasing to F value = 4.2). In contrast, the distribution of TSH was substantially different for untreated individuals versus those on Levothyroxine, where the distribution was massively skewed to low or undetectable TSH with a ‘hockey stick’ configuration, with increasing skewness as doses of Levothyroxine rose. For those not on thyroid hormone replacement, 90.3% of individuals were within the TSH reference range and of these, 0.8% were recorded with a low FT4. For those on medication, only 43.8% were within the TSH reference range. For men versus women, the median Levothyroxine dose was higher in all decades, with the highest median daily dose at age 50–59 years (men: 107 mcg/day; women 93 mcg/day). Median T4 rose (women > men) and TSH fell progressively (women > men) by age in treated individuals. The levels of TSH in treated and untreated populations were only similar at around FT4 = 20pmol/L: below this treated patients have a higher TSH and above it, treated have a lower TSH for the same FT4. Conclusion: We have here described that distribution of FT4/TSH is different in people on and off Levothyroxine treatment. For those on Levothyroxine, only 43.8% were within the TSH reference range and the degree of difference increased in treated individuals with Levothyroxine daily dose. The potential implication of our findings is that clinicians must be mindful as they diagnose and treat hypothyroidism that the administration of Levothyroxine, while in most but not all individuals is clinically beneficial does not return the individual to the same balance of TSH and FT4 as seen in euthyroid individuals.
- Open Access
- 9 July 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (9) , 1813-1827
Improving Diabetes Monitoring in People with Sub-optimally Controlled Diabetes: Implementing a Clinical Laboratory-Led Quality Improvement Initiative in General Practice
Introduction The appropriate use of glycated haemoglobin (HbA1c), the international standard for assessing overall glycaemic status in diabetes mellitus, is critical to ensuring optimal clinical outcome and minimise complications. We describe a clinical laboratory-led general practice service development to facilitate targeted follow-up in high-risk patients. Methods The service development comprised monthly reports identifying high-risk individuals (HbA1c ≥ 58 mmol/mol) overdue HbA1c testing, sent by the Clinical Biochemistry Laboratory to general practices in the ‘Intervention’ group (n = 60). A ‘Non-intervention’ group comprised 51 practices not sent the reports. Comparisons comprised: (i) intervention vs non-intervention groups during two time periods (pre-intervention: 2017–2020; 275,843 tests; 59,206 patients, and post-intervention: 2020–2023; 307,525 tests; 65,449 patients), (ii) pre- versus post-intervention in each group. Results The intervention group (vs non-intervention group) showed larger net change in proportion overdue a test (− 20.6% vs − 10.3%, p < 0.001), particularly in the > 75 mmol/mol category (7.8-fold larger improvement, p < 0.001). Improvements were also observed in median time overdue in the 58–75 mmol/mol group (− 14.3 vs − 4.3%; p = 0.027). Improvements were identified in median HbA1c (p = 0.012) and overall proportion with HbA1c ≥ 58 mmol/mol (p = 0.037), compared with the non-intervention group, despite performing more tests/patient/year (p < 0.001). All remained significant after adjustment for practice characteristics (age, sex, social deprivation, list size, diabetes prevalence) and pre-intervention levels. Conclusions Our findings indicate that clinical laboratories can support general practices facilitating targeting monitoring to high-risk patients. Providing succinct reports that identify patients overdue for testing can reduce the number of such patients, thereby improving diabetes control and increasing the achievement of target levels.
- 9 July 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (9) , 1813-1827
Open AccessImproving Diabetes Monitoring in People with Sub-optimally Controlled Diabetes: Implementing a Clinical Laboratory-Led Quality Improvement Initiative in General Practice
Introduction The appropriate use of glycated haemoglobin (HbA1c), the international standard for assessing overall glycaemic status in diabetes mellitus, is critical to ensuring optimal clinical outcome and minimise complications. We describe a clinical laboratory-led general practice service development to facilitate targeted follow-up in high-risk patients. Methods The service development comprised monthly reports identifying high-risk individuals (HbA1c ≥ 58 mmol/mol) overdue HbA1c testing, sent by the Clinical Biochemistry Laboratory to general practices in the ‘Intervention’ group (n = 60). A ‘Non-intervention’ group comprised 51 practices not sent the reports. Comparisons comprised: (i) intervention vs non-intervention groups during two time periods (pre-intervention: 2017–2020; 275,843 tests; 59,206 patients, and post-intervention: 2020–2023; 307,525 tests; 65,449 patients), (ii) pre- versus post-intervention in each group. Results The intervention group (vs non-intervention group) showed larger net change in proportion overdue a test (− 20.6% vs − 10.3%, p < 0.001), particularly in the > 75 mmol/mol category (7.8-fold larger improvement, p < 0.001). Improvements were also observed in median time overdue in the 58–75 mmol/mol group (− 14.3 vs − 4.3%; p = 0.027). Improvements were identified in median HbA1c (p = 0.012) and overall proportion with HbA1c ≥ 58 mmol/mol (p = 0.037), compared with the non-intervention group, despite performing more tests/patient/year (p < 0.001). All remained significant after adjustment for practice characteristics (age, sex, social deprivation, list size, diabetes prevalence) and pre-intervention levels. Conclusions Our findings indicate that clinical laboratories can support general practices facilitating targeting monitoring to high-risk patients. Providing succinct reports that identify patients overdue for testing can reduce the number of such patients, thereby improving diabetes control and increasing the achievement of target levels.
- Open Access
- 3 February 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (4) , e15520
Consistency of the personalized glycated haemoglobin (pHbA1c) methodology over time in people with type 1 diabetes (T1D) using continuous glucose monitoring
- 3 February 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (4) , e15520
Open AccessConsistency of the personalized glycated haemoglobin (pHbA1c) methodology over time in people with type 1 diabetes (T1D) using continuous glucose monitoring
- Open Access
- 23 October 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (12) , 2475-2487
Unveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data
Introduction Since the introduction of insulin therapy, it has become apparent that type 1 diabetes (T1D) is accompanied by long-term microvascular and macrovascular complications. In the context of the many benefits of continuous glucose monitoring (CGM), there remain opportunities to study the large amount of data now available in order to maximise its potential in the endeavour to reduce the occurrence of diabetes tissue complications in the longer term. Methods Continuous glucose monitoring values were downloaded for 89 type 1 diabetes mellitus (T1D) individuals for up to 18 months from 2021 to 2023. Data for patient demographics was also taken from the patient record which included Sex, Date of Birth, and Date of Diagnosis. The recorded laboratory glycated haemoglobin (HbA1c) test results were also recorded. The glucose management index (GMI) was calculated from average glucose readings for 18 months using the formula GMI (%) = (0.82 − (Average glucose/100)). This was then adjusted to give GMI (mmol/mol) = 10.929 * (GMI (%) − 2.15). Average Glucose Fluctuation (AGF) was calculated by adding up the total absolute change value between all recorded results over 18 months and dividing by the number of results minus one. The % Above Critical Threshold (ACT) was calculated by summing the total number of occurrences for each result value. A cumulative 95% limit was then applied to identify the glucose value that only 5% of results exceeded in the overall population. Using this value, we estimated the percentage of total tests that were above the Critical Threshold (ACT). Results The mean age of the participants was 42.6 years, and the mean duration of T1D was 18.4 years. A total of 3.22 million readings were analysed, yielding an average blood glucose level of 10.3 mmol/l and a GMI of 57.2 mmol/mol. There was a strong correlation between GMI and measured HbA1c (r2 = 0.82). However, there were patients who had an above-critical threshold (ACT) of 4–10% at a GMI of 60 mmol/mol or less. The percentage average value at the time of day (%AVTD) was applied to all blood glucose readings at each 15-min interval throughout the day, averaged over 18 months. The %AVTD of GMI (overall average 57.2 mmol/mol) increased after midday, dipped at 18:00, and peaked at 22:00. The %AVTD of AGF (overall average 0.60 mmol/l) showed higher change rates after 09:00 declining at the end of the day. The %AVTD of ACT peaked at 22:00, with those having the highest %ACT showing an additional peak at 15:00. Conclusions We have shown here that the percentage glucose results above 18 mmol/l (top 5% of distribution) increased exponentially above 54 mmol/mol HbA1c. The %AVTD is introduced as a useful measure. Our data indicate that over the 24-h period, improvement in metabolic control could be focussed on the afternoon and evening, when there are higher-than-average levels of GMI, a higher-than-average degree of glucose change, and higher-than-average risks of being above the critical threshold. In conclusion, a measure of glycaemic variation based on the amplitude of glucose change to a population mean could be used to provide valuable clinical insights into glucose change over a 24-h period.
- 23 October 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (12) , 2475-2487
Open AccessUnveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data
Introduction Since the introduction of insulin therapy, it has become apparent that type 1 diabetes (T1D) is accompanied by long-term microvascular and macrovascular complications. In the context of the many benefits of continuous glucose monitoring (CGM), there remain opportunities to study the large amount of data now available in order to maximise its potential in the endeavour to reduce the occurrence of diabetes tissue complications in the longer term. Methods Continuous glucose monitoring values were downloaded for 89 type 1 diabetes mellitus (T1D) individuals for up to 18 months from 2021 to 2023. Data for patient demographics was also taken from the patient record which included Sex, Date of Birth, and Date of Diagnosis. The recorded laboratory glycated haemoglobin (HbA1c) test results were also recorded. The glucose management index (GMI) was calculated from average glucose readings for 18 months using the formula GMI (%) = (0.82 − (Average glucose/100)). This was then adjusted to give GMI (mmol/mol) = 10.929 * (GMI (%) − 2.15). Average Glucose Fluctuation (AGF) was calculated by adding up the total absolute change value between all recorded results over 18 months and dividing by the number of results minus one. The % Above Critical Threshold (ACT) was calculated by summing the total number of occurrences for each result value. A cumulative 95% limit was then applied to identify the glucose value that only 5% of results exceeded in the overall population. Using this value, we estimated the percentage of total tests that were above the Critical Threshold (ACT). Results The mean age of the participants was 42.6 years, and the mean duration of T1D was 18.4 years. A total of 3.22 million readings were analysed, yielding an average blood glucose level of 10.3 mmol/l and a GMI of 57.2 mmol/mol. There was a strong correlation between GMI and measured HbA1c (r2 = 0.82). However, there were patients who had an above-critical threshold (ACT) of 4–10% at a GMI of 60 mmol/mol or less. The percentage average value at the time of day (%AVTD) was applied to all blood glucose readings at each 15-min interval throughout the day, averaged over 18 months. The %AVTD of GMI (overall average 57.2 mmol/mol) increased after midday, dipped at 18:00, and peaked at 22:00. The %AVTD of AGF (overall average 0.60 mmol/l) showed higher change rates after 09:00 declining at the end of the day. The %AVTD of ACT peaked at 22:00, with those having the highest %ACT showing an additional peak at 15:00. Conclusions We have shown here that the percentage glucose results above 18 mmol/l (top 5% of distribution) increased exponentially above 54 mmol/mol HbA1c. The %AVTD is introduced as a useful measure. Our data indicate that over the 24-h period, improvement in metabolic control could be focussed on the afternoon and evening, when there are higher-than-average levels of GMI, a higher-than-average degree of glucose change, and higher-than-average risks of being above the critical threshold. In conclusion, a measure of glycaemic variation based on the amplitude of glucose change to a population mean could be used to provide valuable clinical insights into glucose change over a 24-h period.
- Open Access
- 16 May 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 101 (1) , 62-68
Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?
Background: Primary hypothyroidism affects about 3% of the general population in Europe. In most cases people with hypothyroidism are treated with levothyroxine. In the context of the 2023 British Thyroid Association guidance and the 2020 Competitions and Marketing Authority (CMA) ruling, we examined prescribing data for levothyroxine, Natural desiccated thyroid (NDT) and liothyronine by dose, regarding changes over the years 2016–2022.Design: Monthly primary care prescribing data for each British National Formulary code were analysed for levothyroxine, liothyronine and NDT.Patients and Measurements: The rolling 12‐month total/average of cost or prescribing volume was used to identify the moment of change. Results included number of prescriptions, the actual costs, and the cost/prescription/mcg of drug.Results: Liothyronine: In 2016 94% of the total 74,500 prescriptions were of the 20 mcg dose. In 2020 the percentage prescribed in the 5 mcg and 10 mcg doses started to increase so that by 2022 each reached nearly 27% of total liothyronine prescribing. The average cost/prescription in 2016 of 20 mcg was £404/prescription and this fell by 80% to £101 in 2022; while the 10 mcg cost of £348/prescription fell by only 35% to £255 and the 5 mcg cost of £355/prescription fell by 38% to £242/prescription. The total prescriptions of liothyronine in 2016 were 74,605, falling by 30% up to 2019 when they started to grow again ‐ most recently at 60,990−15% lower than the 2016 figure, with the result that total costs fell by 70% to £9 m/year.Conclusions: Liothyronine costs fell after the CMA ruling but remain orders of magnitude higher than for levothyroxine. The remaining 0.2% of patients with liothyronine treated hypothyroidism are still absorbing 16% of medication costs. The lower liothyronine 5cmg and 10 mcg doses as recommended by BTA are 240% the costs of the 20 mcg dose. Thus, following latest BTA guidance which recommends the lower liothyronine doses still incurs substantial additional costs vs the prescribing liothyronine in the no longer recommended treatment regime. High drug price continues to impact clinical decisions, potentially limiting liothyronine therapy availability to a considerable number of patients who could benefit from this treatment.
- 16 May 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 101 (1) , 62-68
Open AccessLiothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?
Background: Primary hypothyroidism affects about 3% of the general population in Europe. In most cases people with hypothyroidism are treated with levothyroxine. In the context of the 2023 British Thyroid Association guidance and the 2020 Competitions and Marketing Authority (CMA) ruling, we examined prescribing data for levothyroxine, Natural desiccated thyroid (NDT) and liothyronine by dose, regarding changes over the years 2016–2022.Design: Monthly primary care prescribing data for each British National Formulary code were analysed for levothyroxine, liothyronine and NDT.Patients and Measurements: The rolling 12‐month total/average of cost or prescribing volume was used to identify the moment of change. Results included number of prescriptions, the actual costs, and the cost/prescription/mcg of drug.Results: Liothyronine: In 2016 94% of the total 74,500 prescriptions were of the 20 mcg dose. In 2020 the percentage prescribed in the 5 mcg and 10 mcg doses started to increase so that by 2022 each reached nearly 27% of total liothyronine prescribing. The average cost/prescription in 2016 of 20 mcg was £404/prescription and this fell by 80% to £101 in 2022; while the 10 mcg cost of £348/prescription fell by only 35% to £255 and the 5 mcg cost of £355/prescription fell by 38% to £242/prescription. The total prescriptions of liothyronine in 2016 were 74,605, falling by 30% up to 2019 when they started to grow again ‐ most recently at 60,990−15% lower than the 2016 figure, with the result that total costs fell by 70% to £9 m/year.Conclusions: Liothyronine costs fell after the CMA ruling but remain orders of magnitude higher than for levothyroxine. The remaining 0.2% of patients with liothyronine treated hypothyroidism are still absorbing 16% of medication costs. The lower liothyronine 5cmg and 10 mcg doses as recommended by BTA are 240% the costs of the 20 mcg dose. Thus, following latest BTA guidance which recommends the lower liothyronine doses still incurs substantial additional costs vs the prescribing liothyronine in the no longer recommended treatment regime. High drug price continues to impact clinical decisions, potentially limiting liothyronine therapy availability to a considerable number of patients who could benefit from this treatment.
- Open Access
- 9 April 2024
- Published by Wiley in Diabetic Medicine
- Vol. 41 (7) , e15328
Mortality in people with a diabetes foot ulcer: An update from the Salford podiatry clinic follow‐up study
- 9 April 2024
- Published by Wiley in Diabetic Medicine
- Vol. 41 (7) , e15328
Open AccessMortality in people with a diabetes foot ulcer: An update from the Salford podiatry clinic follow‐up study
- Open Access
- 5 February 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (4) , 1464-1478
Counting the lifetime cost of obesity: Analysis based on national England data
Aim: Obesity has a significant impact on all‐cause mortality rate and overall health care resource use (HCRU). These outcomes are also strongly linked to age, sex and local deprivation of the population. We aimed to establish the lifetime costs of obesity by demographic group/geographic area using published mortality rates and HCRU use for integrated care boards (ICB) in England in the context of costs of therapeutic intervention. Methods: Population and expected mortality rates by age, sex and deprivation were obtained from national data. Obesity class prevalence was taken from the health of the nation study. The published impact of obesity by age, group, sex and deprivation on mortality and HCRU were applied to estimate life years lost and lifetime HCRU [by sex, age band and body mass index (BMI) class for each ICB]. The year 2019 was chosen as the study basis data to avoid influences of COVID‐19 pandemic on obesity rates with application of 2022/23 HCRU values. Outcomes including prevalence, deaths, life years lost, HCRU and lifetime HCRU were compared by age and sex groups across four BMI classes normal/underweight (BMI 2 ), overweight (25‐29.9 kg/m 2 ), obese class I and II (30‐39.9 kg/m 2 ), and obese class III (≥40), with benchmarking being set against all population being BMI 16 years was 45.4 million (51% female). Prevalence: 13.7 million (28% of the total adult population) had a BMI ≥30 mg/m 2 and BMI ≥40 kg/m 2 were 1.50 million (12%) of these 1.0 million (68%) were female and of these 0.6 million 40% were women aged 16‐49 years. In addition, 35% of those with a BMI ≥40 kg/m 2 were in the top deprivation quintile (i.e. overall 20%). Mortality was based on expected deaths of 518K/year, and modelling suggested that if a BMI 70 years reducing BMI from ≥40 to 30‐39.9 kg/m 2 might show an annual decrease in HCRU/person by £777/year for women and £796/year for men but also may not be manifest within that year. However, for the morbidly obese men and women, the potential QALY value lost was £2864 per person per year with the potential for these funds to be applied to intensive weight management programmes, including pharmacotherapy.
- 5 February 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (4) , 1464-1478
Open AccessCounting the lifetime cost of obesity: Analysis based on national England data
Aim: Obesity has a significant impact on all‐cause mortality rate and overall health care resource use (HCRU). These outcomes are also strongly linked to age, sex and local deprivation of the population. We aimed to establish the lifetime costs of obesity by demographic group/geographic area using published mortality rates and HCRU use for integrated care boards (ICB) in England in the context of costs of therapeutic intervention. Methods: Population and expected mortality rates by age, sex and deprivation were obtained from national data. Obesity class prevalence was taken from the health of the nation study. The published impact of obesity by age, group, sex and deprivation on mortality and HCRU were applied to estimate life years lost and lifetime HCRU [by sex, age band and body mass index (BMI) class for each ICB]. The year 2019 was chosen as the study basis data to avoid influences of COVID‐19 pandemic on obesity rates with application of 2022/23 HCRU values. Outcomes including prevalence, deaths, life years lost, HCRU and lifetime HCRU were compared by age and sex groups across four BMI classes normal/underweight (BMI 2 ), overweight (25‐29.9 kg/m 2 ), obese class I and II (30‐39.9 kg/m 2 ), and obese class III (≥40), with benchmarking being set against all population being BMI 16 years was 45.4 million (51% female). Prevalence: 13.7 million (28% of the total adult population) had a BMI ≥30 mg/m 2 and BMI ≥40 kg/m 2 were 1.50 million (12%) of these 1.0 million (68%) were female and of these 0.6 million 40% were women aged 16‐49 years. In addition, 35% of those with a BMI ≥40 kg/m 2 were in the top deprivation quintile (i.e. overall 20%). Mortality was based on expected deaths of 518K/year, and modelling suggested that if a BMI 70 years reducing BMI from ≥40 to 30‐39.9 kg/m 2 might show an annual decrease in HCRU/person by £777/year for women and £796/year for men but also may not be manifest within that year. However, for the morbidly obese men and women, the potential QALY value lost was £2864 per person per year with the potential for these funds to be applied to intensive weight management programmes, including pharmacotherapy.
- Open Access
- 1 December 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (2) , 565-566
Correction to: Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
- 1 December 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (2) , 565-566
Open AccessCorrection to: Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
- Open Access
- 30 September 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (1) , 99-110
Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
Introduction Women are on average diagnosed with diabetes mellitus at later age than men but have higher mortality. As the diagnosis of diabetes mellitus is primarily based on HbA1c, the use of a non-specific reference range and cut point for diabetes mellitus that does not account for gender differences in diabetes could potentially lead to underdiagnosis of diabetes mellitus in women and missed opportunities for intervention. We investigated whether a contributing factor to the later diagnosis in women may be a difference in distribution of HbA1c in premenopausal women versus men of the same age by comparing HbA1c values in men and women across multiple sites in the UK. Methods We analysed the HbA1c levels of 146,907 individuals who underwent single testing only and had HbA1c ≤ 50 mmol/mol between 2012 and 2019 in one laboratory (cohort 1). This was replicated in six laboratories with 938,678 individuals tested between 2019 and 2021 (cohort 2). Results In cohort 1, women < 50 years old had an HbA1c distribution markedly lower than that in men by a mean of 1.6 mmol/mol (p < 0.0001), while the difference in the distribution of HbA1c for individuals aged ≥ 50 years was less pronounced (mean difference 0.9 mmol/mol, p < 0.0001). For individuals under the age of 50, HbA1c in women lagged by up to 10 years compared to men. Similar findings were found in cohort 2. We estimated an additional 17% (n = 34,953) of undiagnosed women aged < 50 years in England and Wales could be reclassified to have diabetes mellitus, which may contribute to up to 64% of the difference in mortality rates between men/women with diabetes mellitus aged 16–50 years. Conclusion The HbA1c cut point for diagnosis of diabetes mellitus may need to be re-evaluated in women under the age of 50 years. Early identification of diabetes mellitus in women has the potential to improve women’s health outcomes in the longer term.
- 30 September 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (1) , 99-110
Open AccessIs the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
Introduction Women are on average diagnosed with diabetes mellitus at later age than men but have higher mortality. As the diagnosis of diabetes mellitus is primarily based on HbA1c, the use of a non-specific reference range and cut point for diabetes mellitus that does not account for gender differences in diabetes could potentially lead to underdiagnosis of diabetes mellitus in women and missed opportunities for intervention. We investigated whether a contributing factor to the later diagnosis in women may be a difference in distribution of HbA1c in premenopausal women versus men of the same age by comparing HbA1c values in men and women across multiple sites in the UK. Methods We analysed the HbA1c levels of 146,907 individuals who underwent single testing only and had HbA1c ≤ 50 mmol/mol between 2012 and 2019 in one laboratory (cohort 1). This was replicated in six laboratories with 938,678 individuals tested between 2019 and 2021 (cohort 2). Results In cohort 1, women < 50 years old had an HbA1c distribution markedly lower than that in men by a mean of 1.6 mmol/mol (p < 0.0001), while the difference in the distribution of HbA1c for individuals aged ≥ 50 years was less pronounced (mean difference 0.9 mmol/mol, p < 0.0001). For individuals under the age of 50, HbA1c in women lagged by up to 10 years compared to men. Similar findings were found in cohort 2. We estimated an additional 17% (n = 34,953) of undiagnosed women aged < 50 years in England and Wales could be reclassified to have diabetes mellitus, which may contribute to up to 64% of the difference in mortality rates between men/women with diabetes mellitus aged 16–50 years. Conclusion The HbA1c cut point for diagnosis of diabetes mellitus may need to be re-evaluated in women under the age of 50 years. Early identification of diabetes mellitus in women has the potential to improve women’s health outcomes in the longer term.
- Open Access
- 17 August 2023
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 39 (8) , e3695
Failure to control conventional cardiovascular risk factors in women with type 2 diabetes might explain worse mortality
Introduction: The standardised mortality rate (SMR) for people with diabetes in England is 1.5–1.7, with differences in outcomes between sexes. There has been little work examining the factors that could have an impact on this or on what may determine sex differences in outcome.Methods: Data were extracted for patients with type 2 diabetes (T2D) in Salford (England) in 2010 for the years up to 2020, including any deaths recorded. Expected deaths were calculated from annual Office of National Statistics mortality rate and life expectancy by age and gender, adjusted for the local Index of Multiple Deprivation (IMD). This provided the SMR deprivation (SMRd), and life expectancy years lost per death (LEYLD). The effects of treatment type, and clinical features on SMRd relative to sex were examined by univariable and multivariable analysis.Results: Data from n = 11,806 (F = 5184; M = 6622) patients were included. Of these, n = 5540 were newly diagnosed and n = 3921 died (F = 1841; M = 2080). In total, n = 78,930 patient years. The expected deaths numbered n = 2596 (adjusted for age, sex, and IMD). Excess deaths were n = 1325 (F = 689; M = 636). Life expectancy years lost (LEYL) 18,989 (F = 9714; M = 9275). SMRd 1.51 (F = 1.60; M = 1.44) and LEYLD 4.84 years (F = 5.28; M = 4.46). The impact of risk factors was not different by sex. However, women had higher prevalence of % diagnosed >65 years of age; % last eGFR 2, and lower prevalence of % prescribed ACE‐inhibitor/ARB, DPP4‐inhibitor and SGLT2‐inhibitor. Applying the male prevalence rate to the female population and expected mortality suggested n = 437 (55%) of excess T2D female deaths were attributed to sex difference in the prevalence of these risk and protective factors.Conclusions: Outcomes in women with T2DM are worse than in men, contributed to by greater prevalence of adverse factors and less prescribing of cardioprotective medication.
- 17 August 2023
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 39 (8) , e3695
Open AccessFailure to control conventional cardiovascular risk factors in women with type 2 diabetes might explain worse mortality
Introduction: The standardised mortality rate (SMR) for people with diabetes in England is 1.5–1.7, with differences in outcomes between sexes. There has been little work examining the factors that could have an impact on this or on what may determine sex differences in outcome.Methods: Data were extracted for patients with type 2 diabetes (T2D) in Salford (England) in 2010 for the years up to 2020, including any deaths recorded. Expected deaths were calculated from annual Office of National Statistics mortality rate and life expectancy by age and gender, adjusted for the local Index of Multiple Deprivation (IMD). This provided the SMR deprivation (SMRd), and life expectancy years lost per death (LEYLD). The effects of treatment type, and clinical features on SMRd relative to sex were examined by univariable and multivariable analysis.Results: Data from n = 11,806 (F = 5184; M = 6622) patients were included. Of these, n = 5540 were newly diagnosed and n = 3921 died (F = 1841; M = 2080). In total, n = 78,930 patient years. The expected deaths numbered n = 2596 (adjusted for age, sex, and IMD). Excess deaths were n = 1325 (F = 689; M = 636). Life expectancy years lost (LEYL) 18,989 (F = 9714; M = 9275). SMRd 1.51 (F = 1.60; M = 1.44) and LEYLD 4.84 years (F = 5.28; M = 4.46). The impact of risk factors was not different by sex. However, women had higher prevalence of % diagnosed >65 years of age; % last eGFR 2, and lower prevalence of % prescribed ACE‐inhibitor/ARB, DPP4‐inhibitor and SGLT2‐inhibitor. Applying the male prevalence rate to the female population and expected mortality suggested n = 437 (55%) of excess T2D female deaths were attributed to sex difference in the prevalence of these risk and protective factors.Conclusions: Outcomes in women with T2DM are worse than in men, contributed to by greater prevalence of adverse factors and less prescribing of cardioprotective medication.